Evidence map›Paper›PMID 41030086›Full record

ArticleBritish journal of haematology2025

Optimizing activation and culture conditions for the production of cord blood-derived CAR-T and natural killer cells.

Naokazu Nakamura, Jiyuan Liao, Yasushi Soda, Mizuho Takahashi, Hiroto Kodera, Yukage Kobari, Yukihiko Hirai, Akifumi Takaori-Kondo, Takashi Okada

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Naokazu NakamuraDivision of Molecular and Medical Genetics, Center for Gene & Cell Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0002-4336-1952
Jiyuan LiaoDivision of Molecular and Medical Genetics, Center for Gene & Cell Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Yasushi SodaDivision of Molecular and Medical Genetics, Center for Gene & Cell Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Mizuho TakahashiDivision of Molecular and Medical Genetics, Center for Gene & Cell Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Hiroto KoderaDivision of Molecular and Medical Genetics, Center for Gene & Cell Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Yukage KobariDivision of Molecular and Medical Genetics, Center for Gene & Cell Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Yukihiko HiraiDivision of Molecular and Medical Genetics, Center for Gene & Cell Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Akifumi Takaori-KondoDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Takashi OkadaDivision of Molecular and Medical Genetics, Center for Gene & Cell Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Funding

Japan Agency for Medical Research and Development JP24bm1523001Japan Agency for Medical Research and Development JP24bm1523007JSPS KAKENHI 24KJ0987
6 · The paper itself

Abstract

Cord blood (CB) is gaining attention as a source of chimeric antigen receptor (CAR) T/NK cells. Many studies have focused on the therapeutic effects, but the methods of activating and culturing T/NK cells without excessive exhaustion during the initial stages of the production of CB-derived CAR-T/NK cells are yet to be established. The activation and culture conditions developed for peripheral blood (PB) CAR-T/NK cells have been used for CB-CAR-T/NK cells, but there are differences in the composition and maturity of PB and CB lymphocytes. Thus, this study aims to optimize activation and culture conditions for the production of CB-CAR-T/NK cells. We compared different doses of various cytokines and found that the balance between activation and exhaustion was best with stimulation with a CD3/CD28 agonist followed by 40 U/mL interleukin (IL)-7+ 40 U/mL IL-15 for PB-T cells; 40 U/mL IL-2+ 40 U/mL IL-7+ 40 U/mL IL-15 for CB-T cells; 40 U/mL IL-2+ 40 U/mL IL-15 for PB-NK cells; and 40 U/mL IL-2+ 200 U/mL IL-15 for CB-NK cells. Using killing assays, we confirmed that these cytokine protocols improved the anti-tumour effects. These results will be useful for the development of CB-CAR-T/NK-cell therapies and suggest the potential of these modalities.

Indexed as

Cell Culture TechniquesFetal BloodImmunotherapy, AdoptiveKiller Cells, NaturalLymphocyte ActivationReceptors, Chimeric AntigenT-LymphocytesCells, CulturedCytokinesHumansInterleukin-15CytokinesInterleukin-15Receptors, Chimeric Antigenactivationchimeric antigen receptor T‐cell therapyculturecytokinesimmunotherapy

Identifiers

PMID41030086
PMCPMC12624202

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.